Payment overview · 2025
General Payments
$166.92
9 reported records · 4 companies
Healthcare provider profile · identity verified
Christin E Honaker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOUISVILLE, KY · NPI 1023199064
Verified facts
What the public records show
CMS Open Payments records show Christin E Honaker, MD received $166.92 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.29 | 44.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.03 | 29.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.57 | 14.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.03 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $166.92 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $74.29 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $74.29 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $74.29 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 434 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 94 |
| Losartan Potassium | Losartan Potassium | 350 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 55 |
| Potassium Chloride | Potassium Chloride | 176 | 52 |
| Metformin Hcl | Metformin Hcl | 166 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 45 |
| Meloxicam | Meloxicam | 115 | 37 |
| Alprazolam | Alprazolam | 114 | 16 |
| Lisinopril | Lisinopril | 111 | 37 |
| Sertraline Hcl | Sertraline Hcl | 105 | 31 |
| Omeprazole | Omeprazole | 103 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 33 |
| Furosemide | Furosemide | 91 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 26 |
| Gabapentin | Gabapentin | 77 | 31 |
| Lorazepam | Lorazepam | 77 | 26 |
| Trazodone Hcl | Trazodone Hcl | 76 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 24 |
| Famotidine | Famotidine | 73 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 23 |
| Jardiance | Empagliflozin | 70 | 19 |
| Montelukast Sodium | Montelukast Sodium | 69 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 17 |
| Bupropion Xl | Bupropion Hcl | 60 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 15 |
| Eliquis | Apixaban | 59 | suppressed |
| Carvedilol | Carvedilol | 58 | 15 |
| Ezetimibe | Ezetimibe | 58 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Farxiga | Dapagliflozin Propanediol | 57 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 20 |
| Metformin Hcl Er | Metformin Hcl | 53 | 17 |
| Tramadol Hcl | Tramadol Hcl | 52 | 13 |
| Valsartan | Valsartan | 52 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 13 |
| Simvastatin | Simvastatin | 48 | 12 |
| Allopurinol | Allopurinol | 47 | 12 |
| Atenolol | Atenolol | 47 | 12 |
| Synthroid | Levothyroxine Sodium | 47 | 15 |
| Januvia | Sitagliptin Phosphate | 46 | 11 |
| Azithromycin | Azithromycin | 43 | 37 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Methylprednisolone | Methylprednisolone | 29 | 25 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Prednisone | Prednisone | 22 | 14 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $166.92 · 9 records | PFIZER INC. | ABRYSVO, Auvelity, COMIRNATY, JARDIANCE, PREVNAR 20, QULIPTA, UBRELVY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error